Real Madrid vs Barcelona, The Beatles vs The Stones – our cultural landscape is filled with intense rivalries which arouse the tribal instincts …
The perception of cannabis has changed significantly over the last decade. While in the not too distant past, weed was associated with an …
2019 has been a fantabulous year for stock investors, with the S&P 500 returning 24% year to date. But here’s the bad news: …
Christmas has arrived early for Advanced Micro Devices (AMD) stock, or you could possibly say it has been Christmas all year long for …
Last week saw a landmark decision by the U.S.
Buy low, sell high — that’s the mantra for making money in the stock market, right? And the first part of the process …
Buoyed by optimism over the label expansion of Amarin’s (AMRN) flagship drug, Vascepa, the fish oil drug maker’s stock has run off to …
The S&P 500 stock index has famously averaged a return of just under 10% over the past near-century — a great rate in …
Tilray’s (TLRY) year-to-date price chart does not make for pretty viewing. On a merciless downward trajectory, the embattled marijuana stock has shed almost …
As earnings season draws to a close, there remain a few intriguing companies who have yet to file their quarterly reports. Among the …
